58.46
0.79%
+0.46
After Hours:
58.46
Immunocore Holdings plc ADR stock is currently priced at $58.46, with a 24-hour trading volume of 403.55K.
It has seen a +0.79% increased in the last 24 hours and a -5.19% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $58.25 pivot point. If it approaches the $59.16 resistance level, significant changes may occur.
Previous Close:
$58.00
Open:
$57.75
24h Volume:
403.55K
Market Cap:
$2.92B
Revenue:
$310.32M
Net Income/Loss:
$-68.31M
P/E Ratio:
-45.59
EPS:
-1.2822
Net Cash Flow:
$-3.09M
1W Performance:
+4.99%
1M Performance:
-5.19%
6M Performance:
+27.34%
1Y Performance:
-1.88%
Immunocore Holdings plc ADR Stock (IMCR) Company Profile
Name
Immunocore Holdings plc ADR
Sector
Industry
Phone
44 1235 438600
Address
92 Park Drive, Milton Park, Abingdon
Immunocore Holdings plc ADR Stock (IMCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-20-23 | Resumed | JP Morgan | Overweight |
Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-31-23 | Initiated | Robert W. Baird | Outperform |
Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-13-23 | Initiated | Needham | Buy |
Aug-16-23 | Initiated | CapitalOne | Overweight |
Jul-17-23 | Initiated | Canaccord Genuity | Hold |
Mar-31-23 | Initiated | Mizuho | Buy |
Mar-30-23 | Initiated | Guggenheim | Buy |
Mar-24-23 | Initiated | Bryan Garnier | Buy |
Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
Nov-30-22 | Initiated | Barclays | Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Overweight |
Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
Aug-08-22 | Initiated | Cowen | Outperform |
Aug-02-22 | Initiated | BTIG Research | Buy |
Feb-08-22 | Initiated | H.C. Wainwright | Buy |
Oct-20-21 | Initiated | Oppenheimer | Outperform |
Mar-02-21 | Initiated | Goldman | Neutral |
Mar-02-21 | Initiated | JP Morgan | Overweight |
Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings plc ADR Stock (IMCR) Latest News
Immunocore announces upcoming presentation and posters at ASCO 2024
GlobeNewswire Inc.
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Benzinga
Immunocore to present at upcoming investor conferences
GlobeNewswire Inc.
Immunocore presented two posters at CROI 2024
GlobeNewswire Inc.
Key Takeaways From Immunocore Hldgs Analyst Ratings
Benzinga
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
GlobeNewswire Inc.
Immunocore Holdings plc ADR Stock (IMCR) Financials Data
Immunocore Holdings plc ADR (IMCR) Revenue 2024
IMCR reported a revenue (TTM) of $310.32 million for the quarter ending December 31, 2023, a +46.79% rise year-over-year.
Immunocore Holdings plc ADR (IMCR) Net Income 2024
IMCR net income (TTM) was -$68.31 million for the quarter ending December 31, 2023, a -5.18% decrease year-over-year.
Immunocore Holdings plc ADR (IMCR) Cash Flow 2024
IMCR recorded a free cash flow (TTM) of -$3.09 million for the quarter ending December 31, 2023, a +95.14% increase year-over-year.
Immunocore Holdings plc ADR (IMCR) Earnings per Share 2024
IMCR earnings per share (TTM) was -$1.4084 for the quarter ending December 31, 2023, a -20.77% decline year-over-year.
About Immunocore Holdings plc ADR
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Cap:
|
Volume (24h):